Momenta Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
11. Dezember 2018 16:05 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing...
UPDATE: Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock
06. Dezember 2018 21:56 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing...
Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock
05. Dezember 2018 16:15 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing...
Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA®
03. Dezember 2018 16:05 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing...
Momenta Pharmaceuticals Announces Publication of Phase 1 Study Data for Anti-FcRn Antibody, M281
07. November 2018 09:45 ET
|
Momenta Pharmaceuticals, Inc.
Full data shows safety, tolerability and proof-of-mechanism in healthy volunteers CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced...
Momenta Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
07. November 2018 06:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the third quarter ended September 30, 2018 and provided a...
Momenta Pharmaceuticals Announces Global Settlement with AbbVie to Enable Commercialization of M923, a Proposed Biosimilar to HUMIRA® (adalimumab)
06. November 2018 16:45 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it has executed agreements with AbbVie Inc., providing license rights for the...
Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2018 Healthcare Conference
06. November 2018 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will present at the Stifel 2018 Healthcare Conference. The presentation is...
Momenta Pharmaceuticals Announces Date of Third Quarter 2018 Financial Results Conference Call and Webcast
31. Oktober 2018 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will release its financial results for the third quarter ended September 30,...
Momenta Pharmaceuticals to Host R&D Day on October 11, 2018
04. Oktober 2018 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it will host a live webcast of its R&D Day on Thursday, October 11, 2018...